Reduced NGF Secretion by HT-29 Human Colon Cancer Cells Treated with a GRPR Antagonist Journal Articles uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • The gastrin-releasing peptide receptor (GRPR) is a therapeutic target in colon cancer. Here we show that the GRPR antagonist RC-3095 (10(-3), 10(-6), or 1 microM) decreases nerve growth factor (NGF) secretion measured by enzyme-linked immunosorbent assay (ELISA) in HT-29 human colon carcinoma cells. The results suggest that decreased secretion of neurotrophins might be a novel mechanism by which GRPR antagonists exert their antiproliferative effects in cancer cells.


  • de Farias, Caroline
  • Stertz, Laura
  • Lima, Rodrigo
  • Kapczinski, Flavio
  • Schwartsmann, Gilberto
  • Roesler, Rafael

publication date

  • June 1, 2009